Bifogade filer
Kurs
+22,61%
Likviditet
9,39 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-06-17 | 08:00 | Bokslutskommuniké 2026 |
2026-03-18 | 08:00 | Kvartalsrapport 2026-Q3 |
2025-12-18 | 08:00 | Kvartalsrapport 2026-Q2 |
2025-09-16 | N/A | Årsstämma |
2025-09-11 | 08:00 | Kvartalsrapport 2026-Q1 |
2025-06-18 | 08:00 | Bokslutskommuniké 2025 |
2025-03-13 | - | Kvartalsrapport 2025-Q3 |
2024-12-12 | - | Kvartalsrapport 2025-Q2 |
2024-09-18 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2024-09-17 | - | Årsstämma |
2024-09-12 | - | Kvartalsrapport 2025-Q1 |
2024-07-15 | - | Extra Bolagsstämma 2025 |
2024-06-18 | - | Bokslutskommuniké 2024 |
2024-03-14 | - | Kvartalsrapport 2024-Q3 |
2023-11-28 | - | Kvartalsrapport 2024-Q2 |
2023-09-06 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2023-09-06 | - | Kvartalsrapport 2024-Q1 |
2023-09-05 | - | Årsstämma |
2023-06-21 | - | Bokslutskommuniké 2023 |
2023-05-17 | - | Extra Bolagsstämma 2024 |
2023-03-16 | - | Kvartalsrapport 2023-Q3 |
2022-12-15 | - | Kvartalsrapport 2023-Q2 |
2022-11-07 | - | Extra Bolagsstämma 2022 |
2022-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2022-08-31 | - | Årsstämma |
2022-08-31 | - | Kvartalsrapport 2023-Q1 |
2022-06-16 | - | Bokslutskommuniké 2022 |
2022-03-15 | - | Kvartalsrapport 2022-Q3 |
2021-12-01 | - | Kvartalsrapport 2022-Q2 |
2021-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2021-08-31 | - | Årsstämma |
2021-08-31 | - | Kvartalsrapport 2022-Q1 |
2021-06-17 | - | Bokslutskommuniké 2021 |
2021-03-18 | - | Kvartalsrapport 2021-Q3 |
2020-12-03 | - | Kvartalsrapport 2021-Q2 |
2020-08-28 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2020-08-27 | - | Årsstämma |
2020-08-27 | - | Kvartalsrapport 2021-Q1 |
2020-06-12 | - | Bokslutskommuniké 2020 |
2020-03-12 | - | Kvartalsrapport 2020-Q3 |
2019-12-05 | - | Kvartalsrapport 2020-Q2 |
2019-08-30 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2019-08-29 | - | Årsstämma |
2019-08-29 | - | Kvartalsrapport 2020-Q1 |
2019-06-14 | - | Bokslutskommuniké 2019 |
2019-05-02 | - | Extra Bolagsstämma 2020 |
2019-03-21 | - | Kvartalsrapport 2019-Q3 |
2018-12-13 | - | Kvartalsrapport 2019-Q2 |
2018-08-31 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2018-08-30 | - | Årsstämma |
2018-08-30 | - | Kvartalsrapport 2019-Q1 |
2018-06-15 | - | Bokslutskommuniké 2018 |
2018-03-21 | - | Kvartalsrapport 2018-Q3 |
2017-12-19 | - | Kvartalsrapport 2018-Q2 |
2017-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2017-08-31 | - | Årsstämma |
2017-08-31 | - | Kvartalsrapport 2018-Q1 |
2017-06-14 | - | Bokslutskommuniké 2017 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Uppsala, Sweden, May 22, 2020. The ASCO educational book 2020 highlights DiviTum® as a solution to address unmet needs within monitoring treatment effect of CDK4/6 inhibitors.
The authors Erik S. Knudsen, PhD at Roswell Park Cancer Center, Geoffrey I. Shapiro, MD, PhD at Dana Farber Cancer Institute and Khandan Keyomarsi, PhD at MD Anderson conclude that: “These preliminary results highlight the potential for serum TK1 activity to act as a noninvasive biomarker for CDK4/6 inhibitor target engagement.” The authors also summarize the clinical trials that demonstrate the ability of DiviTum to identify CDK4/6 treatment resistance.
“It is very rewarding to receive this type of recognition from ASCO, the world's leading professional cancer organization. The authors state that DiviTum® can potentially be a tool for monitoring treatment effect of CDK4/6 inhibitors. I am thrilled that many years of clinical research by our team together with leading breast cancer clinicians has led to positive scientific review in a highly respected setting. We look forward to the results of ongoing clinical studies with DiviTum®,” said Anders Rylander, CEO of Biovica.
ASCO (American Society of Clinical Oncology) gathers cancer professionals across the world and has nearly 45,000 members. ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. Every year in conjunction with the ASCO Annual Meeting, an educational book is issued addressing important topics in oncology.
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.